Does Rallies show Form 4 insider transactions for HAE?

Yes. Rallies tracks HAE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is HAE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HAE. It does not provide personalized investment advice.

HAE (Haemonetics Corporation) Stock Analysis - Insider Trades

Haemonetics Corporation (HAE) is a publicly traded Healthcare sector company. As of May 21, 2026, HAE trades at $59.56 with a market cap of $2.66B and a P/E ratio of 16.25. HAE moved +4.51% today. Year to date, HAE is -27.46%; over the trailing twelve months it is -13.57%. Its 52-week range spans $47.32 to $94.99. Analyst consensus is buy with an average price target of $72.67. Rallies surfaces HAE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading HAE stock inside the company?

Recent HAE insider activity includes KROLL MARK W bought 1.40K, Strong Stewart W sold 4.31K, Lingamneni Anila sold 79, and Lingamneni Anila sold 2.14K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

HAE Key Metrics

Key financial metrics for HAE
Metric	Value
Price	$59.56
Market Cap	$2.66B
P/E Ratio	16.25
EPS	$3.64
Dividend Yield	0.00%
52-Week High	$94.99
52-Week Low	$47.32
Volume	0
Avg Volume	0
Revenue (TTM)	$1.32B
Net Income	$175.44M
Gross Margin	59.35%

Recent HAE Insider Trades

KROLL MARK W bought 1.40K (~$98.78K) on Nov 10, 2025.
Strong Stewart W sold 4.31K (~$393.04K) on Jul 26, 2024.
Lingamneni Anila sold 79 (~$7.11K) on Jul 12, 2024.
Lingamneni Anila sold 2.14K (~$192.24K) on Jul 11, 2024.

Latest HAE News

Haemonetics Q4 EPS of $1.29 Beats Estimates, Up 4% Year-over-Year — May 7, 2026
Haemonetics Forecasts 1.4% Price Hike and €12.5m FX Hit in 2026 — Mar 31, 2026
Haemonetics Gains FDA Clearance for NexSys PCS, Persona PLUS Boosts Yield by Mid-Single Digits — Feb 23, 2026
Haemonetics' Q3 Revenue Hits $339M as Fund Highlights Earnings Beat, Shares Slide 20% — Feb 16, 2026
Haemonetics Hold Rating Persists Despite 6.8% Q3 Surprise, 8.1% Growth Forecast — Feb 6, 2026

HAE Analyst Consensus

7 analysts cover HAE: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $72.67.

Common questions about HAE

Who is trading HAE stock inside the company?: Recent HAE insider activity includes KROLL MARK W bought 1.40K, Strong Stewart W sold 4.31K, Lingamneni Anila sold 79, and Lingamneni Anila sold 2.14K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for HAE?: Yes. Rallies tracks HAE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is HAE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HAE. It does not provide personalized investment advice.